Last updated: September 27, 2026
Errin is a 0.35 mg norethindrone progestin-only oral contraceptive. Its commercial opportunity is driven by low-cost manufacturing, reliable daily-use performance, excipient tolerability, supply continuity, and differentiated packaging rather than by patent exclusivity. The core formulation uses conventional oral-tablet excipients, leaving room for lactose-free, improved-disintegration, moisture-controlled, and adherence-focused product variants.
What is Errin and which active ingredient does it contain?
Errin contains norethindrone, a synthetic progestin used for contraception. Each tablet contains 0.35 mg of norethindrone, and the product is administered once daily without a hormone-free interval.[1]
| Attribute |
Errin |
| Active ingredient |
Norethindrone |
| Strength |
0.35 mg per tablet |
| Dosage form |
Oral tablet |
| Therapeutic class |
Progestin-only contraceptive |
| FDA pathway |
Prescription oral contraceptive |
| Administration |
One tablet daily |
| Primary users |
Patients seeking estrogen-free contraception |
| Reference product category |
Norethindrone 0.35 mg tablets |
Errin belongs to the progestin-only pill category, which includes products prescribed when estrogen-containing contraceptives are unsuitable or undesirable. Relevant patient segments include individuals with estrogen-related contraindications, some breastfeeding patients, and patients seeking an estrogen-free option.
What excipients are used in Errin tablets?
The Errin labeling identifies conventional tablet excipients, including lactose monohydrate, pregelatinized starch, magnesium stearate, and povidone.[1] The exact inactive-ingredient declaration should be assessed against the current product label and National Drug Code presentation because pharmaceutical manufacturers may market norethindrone tablets with different excipient systems.
| Excipient |
Functional role |
Commercial relevance |
| Lactose monohydrate |
Diluent and tablet-mass builder |
Low cost, established supply, potential concern for lactose-avoidant patients |
| Pregelatinized starch |
Binder and disintegrant |
Supports compressibility and tablet breakup |
| Povidone |
Binder and processing aid |
Improves granule cohesion and content uniformity |
| Magnesium stearate |
Lubricant |
Reduces sticking and ejection force during compression |
Because norethindrone is present at a low dose, the excipient system has an important role in achieving blend uniformity. Low-dose products can be vulnerable to segregation, especially when particle-size distributions, bulk densities, or electrostatic properties differ between the active pharmaceutical ingredient and excipients.
What formulation risks are associated with a low-dose norethindrone tablet?
The principal technical risks are:
- Content uniformity at the 0.35 mg strength.
- Blend segregation during transfer and hopper holding.
- Over-lubrication from excessive magnesium stearate.
- Delayed disintegration caused by high compression force or excessive hydrophobic lubrication.
- Moisture-related changes in tablet hardness, friability, and dissolution.
- Supply variation in lactose, starch, or povidone grades.
A robust process should control active-particle-size distribution, blending order, lubricant exposure time, compression force, tablet weight, and in-process content uniformity. Direct compression may reduce process steps, but wet granulation can offer stronger control over flow and segregation where the active ingredient has unfavorable powder properties.
What excipient strategies could differentiate Errin-type products?
The most practical strategy is not to change the active ingredient. It is to create a better tolerated, more robust, or easier-to-use version of the same norethindrone tablet.
Lactose-free formulation
A lactose-free formulation could replace lactose monohydrate with one or more of the following:
- Microcrystalline cellulose
- Mannitol
- Dibasic calcium phosphate
- Compressible starch
- Coprocessed cellulose-based excipients
This approach could target patients who avoid lactose or who associate tablet excipients with gastrointestinal symptoms. It would require comparative work on tablet weight, hardness, dissolution, moisture sensitivity, and manufacturability.
A lactose-free product would not automatically create a strong regulatory exclusivity position. Its value would depend on consumer positioning, payer access, supply reliability, and whether the formulation produced a meaningful performance or tolerability advantage.
Improved disintegration and dissolution
For a low-dose immediate-release tablet, rapid and consistent disintegration can reduce batch variability. A development program could evaluate:
- Crospovidone or croscarmellose sodium as superdisintegrants
- Optimized pregelatinized-starch levels
- Lower lubricant concentration
- Controlled compression force
- Wetting-agent systems where justified
- Particle engineering for the active ingredient
Any reformulation must maintain the expected immediate-release profile and demonstrate pharmaceutical equivalence under the applicable FDA pathway.
Moisture-controlled formulation
Packaging may provide more commercial value than a complex excipient change. Moisture-sensitive tablet systems can benefit from:
- High-barrier blister packaging
- Desiccant-containing bottles
- Induction seals
- Low-moisture excipient grades
- Reduced headspace
- Improved warehouse temperature and humidity controls
A blister presentation may also support adherence by displaying the daily dosing sequence. Errin-type products are taken every day, so packaging that reduces missed doses can have a practical market advantage.
Colorant and allergen minimization
A manufacturer may pursue a formulation without artificial colorants, or with a simplified excipient declaration. The commercial benefit is strongest when the product is positioned for patients who actively review inactive ingredients.
The claim must match the complete formulation, manufacturing aids, capsule or coating components, and supplier declarations. “Dye-free,” “gluten-free,” and “lactose-free” claims require documented controls and consistent raw-material specifications.
What patents protect Errin and norethindrone tablets?
Errin is a mature generic oral contraceptive product. The active ingredient, norethindrone, has been marketed for many decades, and the original compound and early product patents are not meaningful barriers to current generic entry.
| IP category |
Current commercial relevance |
| Original norethindrone compound patents |
Expired or commercially obsolete |
| Original oral-contraceptive formulation patents |
Expired or obsolete |
| Errin-specific formulation patents |
No widely recognized blocking estate identified from the mature product profile |
| Method-of-use patents |
Limited relevance for routine contraceptive use |
| Manufacturing patents |
Potentially relevant only for a proprietary process or unusual solid form |
| Packaging patents |
Possible, but generally narrow and easy to design around |
| Trademark rights |
May protect the Errin name, not norethindrone competition |
The most defensible new intellectual property would likely concern a specific formulation, manufacturing process, solid-state form, impurity-control method, packaging system, or adherence technology. Broad claims covering a conventional norethindrone tablet would face substantial validity and obviousness pressure.
What is the Orange Book status of Errin?
The FDA Orange Book lists approved prescription drug products and, where applicable, patent and exclusivity information.[2] Norethindrone 0.35 mg tablets are generally associated with the mature generic oral contraceptive market rather than an active innovator exclusivity period.
Errin-type products are typically marketed through an abbreviated new drug application rather than as a new chemical entity. The relevant regulatory protections are therefore based on approval status, product quality, supplier controls, and commercial execution, not on remaining pioneer exclusivity.
Are Paragraph IV challenges relevant to Errin?
Paragraph IV litigation is unlikely to be a central risk for a mature norethindrone tablet unless a manufacturer asserts a later-issued formulation or manufacturing patent. A generic applicant seeking approval for a conventional norethindrone 0.35 mg tablet would ordinarily face a substantially different risk profile from an applicant challenging a recently approved branded drug.
Potential disputes could still arise over:
- A newly patented excipient system
- A controlled-release or modified-release formulation
- A novel solid form
- A manufacturing process
- A device or adherence package
- A later-listed method-of-use patent
For a conventional immediate-release tablet, the main barriers are bioequivalence, chemistry-manufacturing-controls documentation, supply qualification, and commercial scale-up.
When does Errin lose exclusivity?
Errin does not have a meaningful remaining new-drug exclusivity period in the commercial sense. Norethindrone tablets compete in a mature generic market, and generic substitution is driven by state substitution rules, payer formularies, wholesaler purchasing, and pharmacy inventory.
A company launching a competing product should distinguish between:
- Patent expiry, which concerns enforceable patent rights;
- Regulatory exclusivity, which concerns FDA approval timing;
- Trademark rights, which concern branding; and
- Commercial exclusivity, which may arise temporarily from supply contracts or preferred formulary placement.
These rights have different durations and do not provide the same market protection.
What commercial opportunities exist for an Errin excipient strategy?
1. Lactose-free norethindrone tablets
The clearest product concept is a lactose-free 0.35 mg tablet. It could target patients who avoid lactose and pharmacies seeking differentiated generic alternatives. The opportunity is strongest if the product maintains a small tablet size, reliable dissolution, and competitive cost.
2. Low-cost, high-reliability supply
Norethindrone tablets have a low active-ingredient cost. Manufacturing economics therefore depend heavily on yield, labor, packaging, quality testing, and inventory management. A supplier with dual-source excipients and a validated alternate manufacturing site could compete on service levels rather than formulation novelty.
3. Patient-adherence packaging
Calendarized blister packs, clear daily sequencing, and refill reminders can differentiate a daily contraceptive. Packaging may generate stronger practical value than a minor excipient adjustment because missed doses directly affect contraceptive reliability.
4. Retail and telehealth distribution
Progestin-only contraception is distributed through retail pharmacies, mail-order channels, reproductive-health clinics, and telehealth providers. A manufacturer can pursue private-label supply, pharmacy-chain contracts, and digital-health partnerships without creating a new active pharmaceutical product.
5. Global-market adaptation
Excipient strategy may differ by region because of local preferences, regulatory standards, and supply availability. A lactose-free version may be more useful in markets where lactose avoidance is common, while a low-cost standard formulation may have greater value in price-sensitive markets.
How strong is the patent estate for Errin?
The patent estate is weak for a conventional norethindrone 0.35 mg tablet because the active ingredient and dosage form are mature. New patent strength would depend on claim specificity and supporting comparative data.
| Potential claim type |
Relative strength |
| Conventional norethindrone tablet with standard excipients |
Low |
| Lactose-free composition without performance advantage |
Low to moderate |
| Defined dissolution or stability profile |
Moderate if technically unexpected |
| Novel solid form with demonstrated manufacturing benefit |
Moderate to strong |
| Proprietary impurity-control process |
Moderate |
| Packaging linked to adherence or stability |
Moderate, usually narrow |
| Broad method-of-use contraception claim |
Low |
A commercially useful patent should tie the excipient system to a measurable technical result, such as improved content uniformity, reduced degradation, enhanced stability, faster disintegration, or lower manufacturing variability.
What generic entry risks exist for Errin?
Generic-entry risk is already embedded in the product category. The principal risks are commercial rather than patent-based:
- Price erosion from multiple norethindrone suppliers
- Pharmacy substitution
- Formulary exclusion
- Wholesaler concentration
- Active-ingredient shortages
- Excipient supply disruption
- Product recalls caused by content-uniformity or dissolution failures
- Patient switching caused by tablet appearance or packaging changes
A differentiated formulation may support a premium only if the manufacturer demonstrates a clear patient or payer benefit. Otherwise, standard norethindrone tablets remain exposed to commodity pricing.
What FDA regulatory pathway applies to a new Errin-like product?
A conventional norethindrone 0.35 mg tablet would generally be developed as an abbreviated new drug application referencing an appropriate FDA-listed reference product. The development program would focus on:
- Pharmaceutical equivalence
- Bioequivalence
- Assay and content uniformity
- Dissolution
- Impurity profile
- Stability
- Container-closure performance
- Current good manufacturing practice compliance
A materially different dosage form, release profile, or delivery system could require a different regulatory strategy. A new excipient not previously used in the relevant route or dosage form may also increase regulatory complexity.
Key Takeaways
- Errin is a 0.35 mg norethindrone progestin-only oral contraceptive.
- The labeled excipients are conventional tablet ingredients, including lactose monohydrate, pregelatinized starch, povidone, and magnesium stearate.[1]
- The strongest formulation opportunity is a lactose-free, stable, rapidly disintegrating tablet with competitive manufacturing economics.
- Packaging can create practical differentiation through adherence support and moisture protection.
- Norethindrone is a mature active ingredient with no meaningful pioneer exclusivity barrier.
- Paragraph IV litigation risk is limited for a conventional immediate-release tablet.
- New patents would need narrow, technically supported claims tied to formulation, manufacturing, stability, solid form, or packaging.
- Commercial success depends on supply reliability, payer access, pharmacy distribution, and product tolerability more than on patent protection.
FAQs
Is Errin lactose-free?
The Errin labeling identifies lactose monohydrate among the inactive ingredients.[1] A lactose-free version would require a different formulation and separate regulatory documentation.
Can a manufacturer substitute excipients in an Errin generic?
Yes, a generic manufacturer may use a different inactive-ingredient system if the product satisfies applicable FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and labeling.
Is norethindrone the same as norethindrone acetate?
No. Norethindrone and norethindrone acetate are different active pharmaceutical ingredients with different regulatory listings, formulation considerations, and product profiles.
Does Errin have biologic or biosimilar competition?
No. Errin is a small-molecule oral tablet. Biosimilar regulation does not apply. Competition comes from generic norethindrone tablets and other contraceptive products.
Can a lactose-free Errin formulation receive patent protection?
Possibly, but lactose replacement alone is unlikely to support broad, durable protection. Stronger claims would require a defined composition linked to an unexpected technical or clinical benefit.
References
- U.S. Food and Drug Administration. (n.d.). Errin (norethindrone) tablets, 0.35 mg: Prescribing information. DailyMed.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Guidance for industry. FDA.
- U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.
